Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
View original at finance.yahoo.comModerna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11) Reports full-year revenue of $1.9 billion, GAAP net loss of $(2.8) billion and GAAP diluted EPS of $(7.26) Reiterate…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
2026 SG&A expenses projected to be approximately $1.0 billion
80% confidenceModerna expects potential propionic acidemia therapeutic data readout in 2026
80% confidenceModerna is poised to deliver up to 10 percent revenue growth through mNEXSPIKE expansion and international strategic partnerships
80% confidenceIntismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% compared to KEYTRUDA alone in five-year Phase 2b adjuvant melanoma data
80% confidence2026 revenue targeting up to 10% growth from 2025 with approximately 50% U.S. and 50% international split
80% confidenceModerna expects potential Phase 2 mRNA-4359 data readout in 2026
80% confidenceIn 2025, Moderna sharpened commercial execution, launched third product and brought online three international manufacturing sites, while advancing mRNA pipeline and lowering annual operating expenses by approximately $2.2 billion
80% confidenceSeasonal vaccines expected to deliver up to 10% revenue growth in 2026
80% confidenceModerna expects potential Phase 3 adjuvant melanoma data in 2026
80% confidence2026 cost of sales expected to be approximately $0.9 billion
80% confidenceModerna looks forward to delivering multiple potential product approvals and late-stage clinical readouts, while driving continued innovation across mRNA platform
80% confidenceYear-end 2026 cash and investments projected to be $5.5 to $6.0 billion, excluding any additional credit facility drawdown
80% confidence2026 R&D expenses anticipated to be approximately $3.0 billion
80% confidence